Search Results
Your search for The matches 34665 pages
Showing 22901 - 22950Lenalidomide/Dexamethasone in High-Risk Smoldering Multiple Myeloma
Long-term follow-up in the phase III QuiRedex trial indicates continued benefit of lenalidomide (Revlimid)/dexamethasone vs observation in preventing disease progression in patients with high-risk smoldering multiple myeloma, as reported by Maria-Victoria Mateos, PhD, of Instituto de Biologia...
HHS Takes Steps to Provide More Information on Clinical Trials to the Public
To make information about clinical trials widely available to the public, the U.S. Department of Health and Human Services (HHS) issued a final rule on September 19 that specifies requirements for registering certain clinical trials and submitting summary results information to ClinicalTrials.gov....
Expect Questions About the FDA Discouraging Use of Ovarian Cancer Screening Tests
The release of a U.S. Food and Drug Administration (FDA) Safety Communication “alerting women about the risks associated with the use of tests being marketed as ovarian cancer screening tests”1 and recommending against using these tests comes not as a result of startling new studies, but from an...
The FDA Urges Physicians and Patients to Forgo Ovarian Cancer Screening Tests
In a Safety Communication directed at women and physicians, the U.S. Food and Drug Administration (FDA) alerted women “about the risks associated with the use of tests being marketed as ovarian cancer screening tests” and recommended “against using currently offered tests to screen for ovarian...
The University of Colorado Cancer Center Names Eric Clambey, PhD, Director of Flow Cytometry Shared Resource
The University of Colorado Cancer Center has named Eric Clambey, PhD, Director of the Flow Cytometry Shared Resource. Dr. Clambey, Assistant Professor in the Department of Anesthesiology, is excited to assume his new role in a vital resource for the cancer center. “My research focuses on the...
The Medical Profession Has to Become Culturally Sensitive to the Needs of LGBT Cancer Survivors
Despite my breast cancer diagnosis 4 years ago, I feel really lucky. My cancer was detected relatively early, stage IIB, during a routine mammogram screening—a test that many of my lesbian friends skip because they don’t want to deal with a medical system steeped in a heterosexual culture that is...
A Space to Heal
We pass them every day on our way to the hospital, the street dwellers of our town in India. Their home consists of a plastic sheet suspended between four poles on the pavement. One day, two women sat under the plastic sheet in happy conversation. It had rained heavily the previous night, and I...
Paul Jacobsen, PhD, Named Associate Director of National Cancer Institute Healthcare Delivery Research Program
Paul Jacobsen, PhD, has been named Associate Director of the National Cancer Institute (NCI) Division of Cancer Control and Population Science’s Healthcare Delivery Research Program. In this position, he will be leading a team at the NCI whose mission is to serve as a catalyst for the field of...
Friendship
Mr. C is almost 90 now, but every summer the boxes of squash, pumpkins, tomatoes, and other vegetables from his truck farm still arrive like clockwork at our door. The cancer that required treatment 17 years ago has never recurred. He’s now struggling with a new problem, recovering from a broken...
Radiologic Associates of Fredericksburg Welcomes Samer Hijaz, MD
Radiologic Associates of Fredericksburg (RAF) has announced that Samer Hijaz, MD, a fellowship-trained interventional radiologist, has joined the practice. The interventional radiologists and vascular surgeons of the RAF serve patients at Virginia Interventional and Vascular Associates, the...
ASCO Recommends ‘Quick Wins’ for National Cancer Moonshot
Last month, ASCO recommended to Vice President Joe Biden several immediate and practical actions the Cancer Moonshot Initiative could take during the remainder of his term in the White House—steps that could make a lasting impact in the effort to discover new cancer treatments. ASCO’s...
ASCO Supports Recent Tobacco Legislation
On August 8, the U.S. Food and Drug Administration’s (FDA) rule giving the agency the authority to regulate e-cigarettes, cigars, hookahs, and pipe tobacco took effect. In May, ASCO applauded the FDA for exercising its congressionally mandated authority to regulate e-cigarettes as a crucial step in ...
Advanced Cancer Care Planning Booklet for Your Patients and Caregivers
The ASCO Answers Advanced Cancer Care Planning booklet contains comprehensive information about how patients can communicate directly and honestly about advanced cancer and end-of-life care with friends, family, children, and the health-care team. Featured content includes: Thorough descriptions...
Are You Ready for MACRA? ASCO Offers Educational Resources and Events to Help Practices Prepare
There are only a few months to go before program changes go into effect under the Medicare Access and CHIP Reauthorization Act (MACRA) on January 1, 2017. MACRA was enacted more than a year ago to replace the Sustainable Growth Rate formula for updates to the Medicare physician fee schedule, and it ...
ASCO International Course Helps Ethiopia Realize Its Goal of Improving Cancer Care
Ethiopia, similar to other African countries, has a significant shortage of physicians. Currently, there are 0.3 physicians for every 100,000 people, a rate that is substantially lower than the 2 physicians per 100,000 people found in the rest of Africa. This year, the First Lady of Ethiopia,...
CCF Conquerors Circle Recognizes Donors
The Conquerors Circle is the Conquer Cancer Foundation’s (CCF) first-ever donor appreciation society. Donors who contribute $1,000 annually are members of the Conquerors Circle. In appreciation for their generous and loyal support of CCF, Conquerors Circle members receive exclusive benefits based...
ASCO President-Elect Bruce E. Johnson, MD, FASCO, Reflects on Volunteer Service, Plans for Presidential Term
Bruce E. Johnson, MD, FASCO, began his term as ASCO President-Elect in June 2016 and will serve as 2017–2018 President. A thoracic cancer specialist, Dr. Johnson is Chief Clinical Research Officer and institute physician at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical...
Bishoy Faltas, MD, Joins Weill Cornell Medicine Hematology and Medical Oncology
On July 1, 2016, Bishoy Faltas, MD, joined the Genitourinary Oncology Program in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. As a laboratory-based physician-scientist, Dr. Faltas will focus on studying mechanisms of mutagenesis and drug resistance in bladder...
Eric Fearon, MD, PhD, Named Director of University of Michigan Comprehensive Cancer Center
Eric Fearon, MD, PhD, has been named Director of the University of Michigan Comprehensive Cancer Center. Dr. Fearon, the Emanuel N. Maisel Professor of Oncology at the University of Michigan, is a nationally recognized investigator in cancer genetics. His research has led to a greater...
Multiple Myeloma Research Foundation to Donate Data to NCI’s Genomic Data Commons
The National Cancer Institute (NCI) recently announced a collaboration with the Multiple Myeloma Research Foundation to incorporate the Foundation’s wealth of genomic and clinical data about the disease into the NCI Genomic Data Commons. NCI’s Genomic Data Commons is a publicly available database...
Susan M. O’Brien, MD, Embraces the Challenge of Balancing Patient Care With Clinical Trial Investigation
Susan M. O’Brien, MD, one of the nation’s foremost leukemia experts, told The ASCO Post that she wanted to become a doctor since her earliest memories. “The idea of being able to help sick people always appealed to me,” said Dr. O’Brien, who was born in Manhattan but spent her formative years in...
Particular HPV Strain Linked to Improved Prognosis for Oropharyngeal Cancer
When it comes to cancer-causing viruses like human papillomavirus (HPV), researchers are continuing to find that infection with one strain may be better than another. In an analysis of survival data for patients with oropharyngeal cancer, researchers from the University of North Carolina (UNC)...
Development and Validation of a Quality Assurance Score for Robot-Assisted Radical Cystectomy
What are the factors that add up to the best outcomes for patients who have surgery to treat cancer? Looking for a better way to measure quality of care and share best practices in surgical oncology, a team from Roswell Park Cancer Institute developed a quality assessment tool and validated it in a ...
Some Gains Reported in Enrollment Disparity in National Lung Cancer Trials
Pang et al found that the enrollment disparity in clinical trials in lung cancer has been reduced in recent years for older patients and women overall, according to a study reported in the Journal of Clinical Oncology. However, disparities persist for elderly women, blacks, Asian/Pacific Islanders, ...
Temozolomide vs Radiotherapy in High-Risk Low-Grade Glioma
In the phase III EORTC (European Organisation for Research and Treatment) 22033-26033 intergroup trial reported in The Lancet Oncology, Baumert et al found no progression-free survival difference between temozolomide chemotherapy and radiotherapy alone in patients with high-risk low-grade glioma....
A Helping Hand, Just in Time: The ASCO Guideline for Managing Chronic Pain in Adult Cancer Survivors
With impeccable timing, as well as considerable forethought and planning, Dr. Paice and colleagues have produced a superb evidence-based guideline on “Management of Chronic Pain in Survivors of Adult Cancers.”1 (See this issue of The ASCO Post.) This summary of well-informed and thoroughly...
ASCO Clinical Practice Guideline on Management of Chronic Pain in Survivors of Adult Cancers
As reported in the Journal of Clinical Oncology by Judith A. Paice, PhD, RN, of Northwestern University, and colleagues, ASCO has released a clinical practice guideline on management of chronic pain in survivors of adult cancers.1 The guideline was based on literature review by an expert panel,...
Small Cell Lung Cancer and Immunotherapy: A Change Is Coming, Just Not Front Line (Yet!)
Ever since the immune checkpoint agents arrived, the pace of clinical investigation in oncology has continued to accelerate with an ever-increasing number of trials of single-agent and combination therapies with novel designs that are transforming our drug-development process. However, even in...
Phase III Trial Finds No Survival Benefit of Adding Ipilimumab to Etoposide/Platinum in Newly Diagnosed Extensive-Stage SCLC
In a phase III trial (CA184-156) reported in the Journal of Clinical Oncology by Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, Germany, and colleagues, the addition of the anti–CTLA-4 (cytotoxic T-lymphocyte–associated protein 4) checkpoint inhibitor ipilimumab (Yervoy) to...
Amelie G. Ramirez, DrPH, Receives AACR Distinguished Lecture on the Science of Cancer Health Disparities
The American Association for Cancer Research (AACR) Distinguished Lecture on the Science of Cancer Health Disparities, funded by Susan G. Komen, honors an investigator whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or...
Which Factors Influence Radiotherapy for Brain Metastases?
The advent of more effective systemic therapies, which extend patients’ lives, has also resulted in an increasing incidence of brain metastases, for which clinicians must determine appropriate treatment. Whole-brain radiotherapy has been the traditional treatment modality, but stereotactic...
New Edition of The MD Anderson Manual of Medical Oncology
The third edition of The MD Anderson Manual of Medical Oncology was recently published, offering detailed updates on the personalized multidisciplinary approach to cancer management and treatment of common and rare cancers by specialists at The University of Texas MD Anderson Cancer Center. The...
John Karanicolas, PhD, Joins the Fox Chase Cancer Center Molecular Therapeutics Program
John Karanicolas, PhD, has joined the Fox Chase Cancer Center as Associate Professor in the Molecular Therapeutics Program. Dr. Karanicolas, a computational chemist, earned his doctorate from the Scripps Research Institute. He completed his postdoctoral fellowship at the University of Washington....
Friends of Cancer Research Honors Oncology Leaders at 20th Anniversary and Announces Partnership
Friends of Cancer Research (Friends) celebrated its 20th anniversary September 21 at a special event in Washington, DC. The event honored Janet Woodcock, MD; Eric Lander, PhD; and Sean Parker. Dr. Woodcock, Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug...
Clinical Trials Actively Recruiting Patients With Early Breast Cancer
Pilot Study Title: Pilot Trial of an Implantable Microdevice for in Vivo Drug Sensitivity Testing in Patients With Early-Stage, HER2-Positive, or Triple-Negative Breast Cancer Receiving Neoadjuvant Therapy Study Type: Pilot/interventional/single-group assignment Study Sponsor and Collaborators:...
Using Watson to Analyze Genomic Data to Personalize Treatment for Patients With Cancer
Three years ago, IBM’s Watson supercomputer was best known for defeating two former champions on the TV game show Jeopardy! Today, it is grabbing headlines for becoming an important assistant in cancer care. Able to read and understand millions of pages of text within seconds, Watson caught the...
University of Michigan Cancer Center Names Four New Leaders
The University of Michigan (U-M) Comprehensive Cancer Center has appointed four new leaders to oversee the direction and operation of its research enterprise. Pavan Reddy, MD, Deputy Director Alnawaz Rehemtulla, PhD, Associate Director for Shared Resources Anne Schott, MD, Associate Director for...
2016-2017 Oncology Meetings
OCTOBER American College of Surgeons Clinical CongressOctober 16-20 • Washington, DCFor more information:www.facs.org/clincon2016 ACCC 33rd National Oncology ConferenceOctober 19-21 • St. Louis, Missouri For more information: www.accc-cancer.org/meetings/slideshow-NOC2015/NOC2015.asp 48th Annual...
Daratumumab Plus Bortezomib/Dexamethasone: Changing the Treatment Paradigm in Relapsed or Refractory Myeloma
The CD38 antigen was first recognized on normal and abnormal plasma cells over 3 decades ago. Indeed, this antigen was originally classified as T10, as it was the tenth antigen described on T cells. Its distribution of expression included activated B and T cells, natural killer cells, leukocytes,...
Susan G. Komen Announces $27 Million Initiative to Reduce Breast Cancer Deaths in African American Community
The Susan G. Komen breast cancer organization gathered philanthropic, civic, medical, and business leaders in Washington, DC, September 14 to formally launch a $27 million, 10-city initiative to reduce breast cancer death rates among African American women. “African American women are almost 40%...
Oncology Researchers, Clinicians Selected as Endocrine Society 2017 Laureate Award Winners
The Endocrine Society selected 14 leaders in the endocrinology field as winners of the organization’s prestigious 2017 Laureate Awards. Established in 1944, the Laureate Awards recognize the highest achievements in the endocrinology field. Three oncology leaders in particular were recognized for...
Jacques Galipeau, MD, FRCP(C), Brings Personalized Stem Cell Treatment to UW Carbone
An international leader in harnessing a patient’s own stem cells to fight cancer and autoimmune diseases joined the faculty of the University of Wisconsin (UW) Carbone Cancer Center on September 1. Jacques Galipeau, MD, FRCP(C), came from the Winship Cancer Center at Emory University, where he...
Study Finds Adding Daratumumab to Bortezomib/Dexamethasone Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma
In the phase III CASTOR trial reported in The New England Journal of Medicine, Antonio Palumbo, MD, of the University of Turin, and colleagues found that adding the anti-CD38 antibody daratumumab (Darzalex) to bortezomib (Velcade) and dexamethasone markedly improved progression-free survival among ...
Internationally Renowned Statistician on Cancer Clinical Trials, Daniel J. Sargent, PhD, Dies
In the 20th century, the field of statistics developed and was gradually applied to clinical research. The use of statistics allows clinical researchers to form reasonable and accurate inferences from collected information and to make sound decisions in the presence of uncertainty. Moreover,...
Why Care About the Caregivers?
Caregivers of patients with cancer provide invaluable health-care services, but they are an underserved and undervalued group, with many unmet needs. Early palliative care may provide important benefits to these often tireless individuals, according to J. Nicholas Dionne-Odom, PhD, RN, ACHPN, of...
Benefits of Early Palliative Care Interventions Extend Beyond the Patient
A session at the 2016 Palliative Care in Oncology Symposium focused on the special needs of cancer caregivers. In a large survey, caregivers of persons with cancer reported higher levels of stress and significantly more duties than caregivers of other patients. But, according to research from...
Palliative Care: Let’s Use the Tools We Already Have
Clinicians and researchers in the field of palliative and supportive care are enjoying the recognition the field is now receiving and expecting the future to be ripe with opportunity. But one thought leader in this specialty had a suggestion for attendees at the 2016 Palliative Care in Oncology...
Pearls for Managing Immune-Related Toxicities
With checkpoint inhibitors in frequent use, clinicians strive daily to balance the efficacy and toxicity of these treatments. At the 2016 Palliative Care in Oncology Symposium, Lynn M. Schuchter, MD, FASCO, the C. Willard Professor of Hematology-Oncology at the University of Pennsylvania,...
Immunotherapy Brings Unique Challenges for Clinicians
The advent of immunotherapies has created a number of interesting challenges for oncology providers. At the 2016 Palliative Care in Oncology Symposium, specialists in the field tackled these issues. “There is a lot of newness to how we approach patient care with immunotherapies on board,” said...
Why Curing Cancer Will Take Decades
This past summer, Eric S. Lander, PhD, President of the Broad Institute of the Massachusetts Institute of Technology and Harvard in Cambridge, Massachusetts, and Co-Chair of the President’s Council of Advisors on Science and Technology, raised a few eyebrows at the Aspen Ideas Festival when he...
